Honored to have joined Istituto Tumori with Nadia Zaffaroni and Sandro Pasquali for a few months of research in #sarcoma . Thanks Universidad de Castilla-La Mancha for the chance to keep our research abroad and improve our experimental models.

We close out Day 3 of #SPAGN2024 with a fascinating conversation on AI. Maria Brandt of Deutsche Sarkom-Stiftung talked about using ChatGPT & AI assisted tools to save time creating content & increase your reach. And Dr. Sandro Pasquali spoke about using AI to support #sarcoma research.

Gist session ends with a focus on the role of local treatments in oligometastatic disease.
📊 More options but still a lot of questions: who, when, where?
💉 Could liquid biopsy help in patients selection?
Multidisciplinary discussion is crucial!!

#ISG #gist

Brilliant summary of cellular therapy at #ISG
🌟 Lecture of Dr. Ignazio Caruana from University Children's Hospital of Wurzburg, on its use in #sarcomas shines a light of hope for the future of these tumors treatment.

Alessandra Merlini

La coordinazione tra medici e associazioni Pazienti può portare ad aprire tavoli di lavoro con le istituzioni e la giornata di oggi ne è la prova! Italian Sarcoma Group Associazione EHE ITALIA ODV Desmoid Foundation ONLUS - Italia #sarcoma

⚔️ Exciting discussion during the second battle at #ISG annual meeting on the benefits and drawbacks of dose dense chemotherapy in Ewing Sarcoma!!
↔️ Different viewpoints brought to light the complexities of this treatment approach!!
#ewingsarcoma #dosedense #chemotherapy

The second day of #ISG annual meeting kicks off with an interesting educational session on #bone sarcomas.
👥 Collaboration between pediatric and adult oncologists is crucial for comprehensive care across all ages!!

#bone sarcoma Emanuela Palmerini Silvia Stacchiotti

After the pre-meeting sessions clinical study coordinators and patients advocates led, the official opening of the annual meeting is going live. Our predident Silvia Stacchiotti gives her overview of the Italian Sarcoma Group activities of the past 3 years during her presidency

🔸Grow #ISG in its mission of research, education and improving patient care;
🔶strengthen and expand activities, wg, collaboration networks;
🔸 enhance and stimulate common effort of members:
Silvia Stacchiotti sums up 3 yrs of ISG presidency with the Board of Directors.
#sarcoma

Excellent talk from Prof Paolo G Casali on the controversial world of surrogate endpoints in clinical research today!!
📌 Are they reliable indicators of treatment efficacy or just a shortcut?
Great debate at #ISG annual meeting ✔️

#sarcoma Alessandro Gronchi
antonella brunello Rosalba Miceli

Are #RECIST still the best criteria for assessing #tumor response? Preplanned analysis of ISG 1001 (AI neoad CTx vs histo-tailored neoad CTx in soft tissue #sarcoma ) show inverse correlation between response and survival, regardless of RECIST threshold. Italian Sarcoma Group

Today the #departmentbreakfast Istituto Tumori is about #retroperitoneal #sarcoma ❕Incidence of about 0.5/100k/yr, 80 new #patients with primary RPS resected each year in #Milan . Does volume help moving the needle?

The new uterine sarcoma guidelines are ready to present at #ESGO2024 in Barcelona! The guidelines working group, which is a collaboration between ESGO, EURACAN and GCIG, held its last meeting in Milan 🇮🇹 this week at L'Istituto Nazionale dei Tumori to finalize the…

Claudio Vernieri, ricercatore AIRC presso @ifom_milan si è avvicinato alla #ricerca sul cancro anche per motivi personali: a 13 anni ha infatti perso la nonna materna per un carcinoma gastrico avanzato.

Oggi ci ricorda che il #cancro è una malattia che nasce nel nostro…

Stefania ha sempre pensato che da grande sarebbe diventata astrofisica. Al liceo l'avvicinamento per la prima volta all'oncologia l'hanno portata a cambiare strada per dedicarsi alla medicina: 'L’aspetto emotivo e quello scientifico della medicina sono stati i motori principali…

Localized primary High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of R Trial From Italian Sarcoma Group GEIS , French (FSG), and Polish Sarcoma Groups (PSG): trabectedin is not inferior to AI when neoadjuvant chemotherapy is a consideration. ascopubs.org/doi/10.1200/JC…

FORTRESS 2024 final program now online! A lot of hard preparatory work went into this, and we are pretty excited about the outcome. This will be such a cool workshop again. kuleuven.be/fortress/progr…

#Postdoc position available on #sarcoma #Immunity at Molecular Pharmacology of Istituto Tumori - if interested please contact [email protected]

At the cutting edge of sarcoma/gist/desmoid management and research! Marco Fiore, MD, FACS, FEBSh Stefano Radaelli Dario Callegaro Sandro Pasquali Italian Sarcoma Group EORTC CTOS Society of Surgical Oncology European Society of Surgical Oncology (ESSO) AnnalsSurgOncology European Journal of Surgical Oncology

1500 new patients per year seen in consultation, 3500 follow up visit, 450 new sarcoma/GIST/desmoid patients managed each year (>1/10 of the incidence patients in Italy), a few millions € of grants for research, over 10 clinical studies open to recruitment or follow up. 3/4